On the stock market since 2007, it operates in the world of health and science. It has 50 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Revenue is spread across several lines; no single product carries the company.
Average growth of 30% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 21% a year on average.
Sales run at $52.6M a year. A small number, but proof the product has real buyers.
A loss of $81.7M against $52.6M in annual sales.
The stock sits at $0.20. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, NEPT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NEPT is a high-risk stock — not yet profitable, and its future rides on its product catching on.